Fluorothymidine F-18
Phase 1Small molecule
Fluorothymidine F-18 is one of 87 small molecule programs targeting Breast Cancer. It is currently in Phase 1.
2
Indications
5
Total Trials
1
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia1 trial
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
Recruiting·—·Phase 1·NCT03422731·74 enrolled
Breast Cancer1 trial
PET/CT Imaging1 trial
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Completed·—·Phase 2·NCT01717391·36 enrolled
Soft Tissue Sarcoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluorothymidine F-18. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MM.D. Anderson Cancer Center